Credit Corp Group (ASX:CCP) Releases FY25 Market Update
Credit Corp Group (ASX:CCP) outlines its FY25 financial targets and strategic growth initiatives across US and Australian/NZ markets in its latest market update.
Category: Companies
Regis Healthcare Limited (ASX:REG) Reports Strong H1 FY25 Financial Performance
Regis Healthcare Limited (ASX:REG) reports a 17.5% revenue increase in H1 FY25, highlighting significant growth and financial stability.
Spectur Limited (ASX:SP3) Appoints New CEO and Reports Strong Revenue Growth
Spectur Limited (ASX:SP3) appoints Anthony Schmidt as CEO and reports over $7M revenue for FY2023, highlighting strong growth and strategic expansion.
Brightstar Resources Limited (ASX:BTR) Announces Gold Drilling Results
Brightstar Resources (ASX:BTR) announces significant gold drilling results, advancing exploration and operational activities.
Swift Networks Group Ltd (ASX:SW1) Closes $3.3 Million Entitlement Offer
Swift Networks Group Ltd (ASX:SW1) closes $3.3M entitlement offer, raising $2.3M to fund product development and reduce debt.
Generation Development Group Limited (ASX:GDG) Forms Strategic Alliance with BlackRock
Generation Development Group Limited (ASX:GDG) partners with BlackRock to develop holistic retirement solutions for Australian retirees.
Algorae Pharmaceuticals (ASX:1AI) Partners with Peter MacCallum Cancer Centre for AI-Driven Drug Screening
Algorae Pharmaceuticals (ASX:1AI) partners with Peter MacCallum Cancer Centre to validate AI-driven drug synergies in oncology.
Pro Medicus Limited (ASX:PME) Signs A$20M Contract with University of Iowa Health Care
Pro Medicus Limited (ASX:PME) signs a A$20M, 5-year contract with University of Iowa Health Care for its cloud-based Visage 7 platform.
Helloworld Travel Limited (ASX:HLO) Updates FY25 Guidance and Reports Strong Operational Performance
Helloworld Travel (ASX:HLO) revises FY25 UEBITDA guidance due to market volatility, while reporting strong operational performance.
Nyrada Inc. (ASX:NYR) Announces Positive Preclinical Study Results for NYR-BI03
Nyrada Inc. (ASX:NYR) reports significant cardioprotective findings for NYR-BI03 in preclinical studies, demonstrating potential for treating heart attack-related conditions.